Appendix 6 (as supplied by the authors): Sensitivity analysis of age-specific annual percent change (95 % confidence interval) of the most recent trend for selected cancer sites excluding Quebec data.

Cancer sites	Sex	Age (years) 20-29	30-39	40-49	50-59	60-69	70-79	80-89
		Annual percent change (95% confidence interval)						
Anal	F		2.16 (1.23, 3.10)		2.81 (2.18, 3.44)	1.91 (1.39, 2.44)	0.93 (0.31, 1.55)	-0.85 (-1.69, -0.01)
	M		1.37 (0.44, 2.31)		0.72 (-0.03, 1.48)	-0.75 (-1.62, 0.14)	-4.48 (-7.18, -1.70)	-0.64 (-1.74, 0.47)
Bladder	F	-1.92 (-2.74, -1.10)		-2.87 (-3.90, -1.84)	-1.67 (-2.13, -1.21)	-0.60 (-0.87, -0.32)	-0.24 (-0.47, -0.01)	0.04 (-0.25, 0.32)
	M	-3.40 (-4.13, -2.66)		-2.51 (-2.96, -2.07)	-2.17 (-2.61, -1.73)	-1.25 (-1.59, -0.92)	-0.56 (-0.83, -0.28)	-0.28 (-0.48, -0.08)
Breast	F	3.00 (1.82, 4.19)	-0.05 (-0.18, 0.07)	-0.00 (-0.09, 0.08)	-1.03 (-1.28, -0.77)	0.15 (-0.07, 0.36)	-0.24 (-0.48, 0.01)	-6.30 (-8.88, -3.65)
Cervix	F	-1.72 (-2.02, -1.42)	-1.23 (-1.44, -1.01)	-1.12 (-1.38, -0.85)	-1.59 (-1.89, -1.29)	-3.24 (-3.44, -3.04)	-3.27 (-3.52, -3.01)	-3.46 (-3.82, -3.09)
Colorectal	F	7.93 (4.69, 11.28)	3.41 (2.46, 4.38)	2.03 (1.25, 2.81)	-0.59 (-0.71, -0.48)	-0.85 (-0.96, -0.73)	-0.61 (-0.72, -0.49)	-8.70 (-11.65, -5.65)
	M	5.17 (3.30, 7.07)	5.41 (3.98, 6.86)	1.97 (1.23, 2.71)	-0.28 (-0.45, -0.10)	-2.70 (-3.40, -1.99)	-1.96 (-2.64, -1.27)	-5.14 (-7.38, -2.84)
Endometrium	F	-1.12 (-2.07, -0.16)	4.50 (3.14, 5.87)	2.44 (1.76, 3.12)	1.36 (1.14, 1.58)	2.04 (1.76, 2.32)	3.10 (1.83, 4.38)	-1.17 (-1.74, -0.59)
Kidney	F	1.25 (0.43, 2.07)	2.13 (1.53, 2.73)	1.57 (1.09, 2.04)	1.43 (1.15, 1.71)	1.52 (1.27, 1.76)	0.90 (0.47, 1.34)	-5.94 (-10.43, -1.22)
	M	0.75 (-0.09, 1.59)	2.21 (1.53, 2.88)	1.86 (1.60, 2.12)	0.91 (0.65, 1.17)	1.03 (0.74, 1.33)	1.26 (1.06, 1.47)	-2.88 (-4.84, -0.87)
Liver	F	-1.31 (-2.26, -0.36)		-0.61 (-1.40, 0.19)	0.91 (-0.25, 2.08)	1.42 (0.74, 2.10)	1.41 (1.01, 1.81)	1.44 (1.08, 1.81)
	M	-1.26 (-1.95, -0.56)		0.30 (-0.57, 1.18)	-4.27 (-6.63, -1.85)	-3.74 (-7.49, 0.17)	3.15 (2.83, 3.46)	2.58 (2.32, 2.85)
Lung	F	0.47 (-0.52, 1.47)	-3.87 (-5.10, -2.63)	-6.47 (-8.86, -4.03)	-0.91 (-1.11, -0.71)	-1.36 (-1.94, -0.78)	1.56 (1.30, 1.82)	-8.08 (-14.42, -1.26)
	M	-0.30 (-1.15, 0.56)	-2.92 (-3.40, -2.44)	-10.21 (-15.77, -4.27)	-3.39 (-3.54, -3.24)	-2.66 (-2.77, -2.55)	-1.24 (-1.35, -1.13)	-8.12 (-14.98, -0.71)
Melanoma	F	-0.45 (-0.83, -0.06)	-0.45 (-0.74, -0.15)	0.43 (0.12, 0.74)	1.65 (1.44, 1.86)	2.75 (2.48, 3.02)	2.87 (2.67, 3.07)	2.56 (2.23, 2.88)
	M	-0.47 (-0.93, -0.00)	-0.83 (-1.21, -0.45)	-0.34 (-0.72, 0.06)	0.80 (0.50, 1.10)	2.38 (2.11, 2.65)	3.58 (3.24, 3.92)	3.99 (3.60, 4.38)
NHL	F	1.23 (0.71, 1.75)	1.00 (0.62, 1.38)	-0.62 (-1.20, -0.02)	-0.19 (-0.65, 0.27)	0.14 (-0.38, 0.65)	1.64 (1.48, 1.79)	1.17 (0.90, 1.44)
	M	0.67 (0.13, 1.20)	1.15 (-0.08, 2.39)	-0.17 (-0.54, 0.19)	0.10 (-0.36, 0.56)	1.12 (0.87, 1.36)	1.44 (1.21, 1.68)	1.97 (1.75, 2.20)
Ovary	F	-0.49 (-1.00, 0.03)	-1.06 (-1.40, -0.71)	0.47 (-0.13, 1.08)	-1.20 (-1.35, -1.06)	-0.93 (-1.05, -0.80)	-0.42 (-0.58, -0.26)	-5.02 (-7.02, -2.98)
Pancreas	F	4.36 (2.54, 6.22)		-0.18 (-0.70, 0.34)	-0.03 (-0.27, 0.21)	-0.10 (-0.30, 0.10)	-0.17 (-0.33, -0.01)	-11.61 (-16.95, -5.93)
	M	0.14 (-0.82, 1.11)		1.85 (0.17, 3.55)	-0.73 (-0.95, -0.51)	0.96 (-0.05, 1.97)	0.72 (-0.30, 1.76)	-1.12 (-1.34, -0.90)
Prostate	M	-1.41 (-2.29, -0.53)		-12.57 (-17.49, -7.35)	-6.53 (-8.06, -4.99)	-6.17 (-7.42, -4.91)	-5.38 (-7.16, -3.57)	-4.15 (-4.47, -3.83)
Stomach	F	-0.58 (-1.31, 0.15)		0.69 (-0.31, 1.70)	0.94 (-0.68, 2.58)	-2.20 (-2.43, -1.97)	-1.66 (-2.12, -1.19)	-3.06 (-3.26, -2.85)
	M	-1.00 (-1.61, -0.38)		-1.59 (-1.91, -1.27)	6.65 (-2.07, 16.14)	-2.19 (-2.31, -2.06)	-1.49 (-2.00, -0.98)	-2.43 (-2.59, -2.26)
Thyroid	F	3.60 (3.27, 3.92)	3.10 (2.16, 4.05)	0.48 (-4.01, 5.19)	-6.58 (-17.11, 5.28)	-0.22 (-5.59, 5.46)	6.60 (5.79, 7.42)	2.77 (1.86, 3.69)
	M	2.86 (2.18, 3.54)	4.81 (4.28, 5.35)	7.84 (6.90, 8.79)	4.85 (4.45, 5.26)	5.01 (4.51, 5.50)	6.50 (4.91, 8.11)	1.11 (0.39, 1.84)

The most recent trend is the curve fitted to the period that starts from the last joinpoint and ends at year 2015.

Notes: To determine how robust our results were to imputation methods for the final four years of incidence data for Quebec, we repeated our analyses excluding this province. These secondary results of age-specific incidence trends for selected cancer sites are presented in Appendix 3. Overall, the results between our primary analysis and the sensitivity analysis are relatively consistent with the exception of anal cancer among older age groups and thyroid cancer in younger age groups. The results for thyroid cancer could reflect practices related to different rates of over-diagnosis in Quebec and the rest of Canada.